Objective: Patients with end-stage renal disease can exhaust all upper extremity access options. Lower extremity access is often considered for the next vascular access option in these patients. We describe our contemporary experience with the autogenous femoral vein transposition arteriovenous fistula (FVT).
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Methods: All FVTs performed at an academic medical center were analyzed from 2006 to 2017. FVTs were placed after upper extremity access was deemed no longer feasible. The patients' demographics, comorbidities, and access history were described, and perioperative and long-term outcomes were analyzed.
Results: Eighteen patients who received FVT were identified. Mean age was 56 6 12 years; 28% were female, and 67% were African American. Comorbidities included hypertension (100%), coronary artery disease (67%), diabetes (67%), congestive heart failure (50%), and obesity (39%). The median number of previous upper extremity accesses was three, and all patients dialyzed through a tunneled line at the time of the operation. The median operative time was 255 minutes, and estimated blood loss was 150 mL. Preanastomotic banding was performed in 89% of cases.
Four (22.2%) patients returned to the operating room within 30 days for drainage of thigh abscess, revision and thrombectomy of the access, hematoma drainage, and colectomy for Clostridium difficile colitis. Other perioperative complications included wound complications (27.8%), deep venous thrombosis (5.6%), myocardial infarction (non-ST-segment elevation myocardial infarction; 5.6%), pneumonia (5.6%), and urinary tract infection (5.6%). Distal arterial ischemia requiring revascularization occurred in one (5.9%) patient at 6 months. No patients died within 30 days, whereas one died within 90 days. Three patients had an emergency department visit within 30 days and two were admitted. Eighty percent of patients' FVTs matured, and they underwent successful dialysis through the FVT. At 1 year, primary patency was 73.5%, assisted primary patency was 94.1%, and secondary patency was 94.1%.
Conclusions: FVT provides excellent long-term durability in patients with limited dialysis options. It should be considered in appropriate-risk patients who have exhausted their upper extremity options. 
